BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, Sakaida I, Terai S, Yokosuka O, Shimizu M, Takikawa H. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res. 2018;48:219-224. [PMID: 29361652 DOI: 10.1111/hepr.13066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Reference Citation Analysis]
3 Uchida Y, Inao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis. Hepatol Res 2020;50:1355-64. [PMID: 32886950 DOI: 10.1111/hepr.13566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, Terai S. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019;39:18. [PMID: 31516638 DOI: 10.1186/s41232-019-0107-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
5 Sukezaki A, Chu PS, Shinoda M, Hibi T, Taniki N, Yoshida A, Kawaida M, Hori S, Morikawa R, Kurokouchi A, Wakino S, Kameyama K, Obara H, Kitagawa Y, Saito H, Kanai T, Nakamoto N. Late-onset acute liver failure due to Wilson's disease managed by plasmapheresis and hemodiafiltration successfully serving as a bridge for deceased donor liver transplantation: a case report and literature review. Clin J Gastroenterol 2020;13:1239-46. [PMID: 32643122 DOI: 10.1007/s12328-020-01175-8] [Reference Citation Analysis]
6 Miwa T, Hatano Y, Kochi T, Aiba M, Toda K, Goto H, Nakamura N, Katsumura N, Imai K, Shimizu M. Spur cell anemia related to alcoholic liver cirrhosis managed without liver transplantation: a case report and literature review. Clin J Gastroenterol 2020;13:882-90. [PMID: 32472376 DOI: 10.1007/s12328-020-01142-3] [Reference Citation Analysis]
7 Yang L, Wu T, Li J, Xin J, Shi D, Jiang J, Liang X, Lu Y, Yao H, Zhang H, Sun S, Li T, Mohamed Hassan Mohamed H, Li J, Ren K, Guo B, Zhou X, Chen J, Hao S, Chen J, Xin S, Pan C, Han T, Chen Y, Lin S, Duan Z, Xu X, Huang J, Chen X, Li L, Li J; Chinese Group on the Study of Severe Hepatitis B (COSSH). Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis. Hepatol Res 2020;50:656-70. [PMID: 32134538 DOI: 10.1111/hepr.13497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Koya Y, Shibata M, Watanabe T, Kumei S, Miyagawa K, Oe S, Honma Y, Kume K, Yoshikawa I, Harada M. Influence of gastroesophageal flap valve on esophageal variceal bleeding in patients with liver cirrhosis. Dig Endosc 2021;33:100-9. [PMID: 32274835 DOI: 10.1111/den.13685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kuramitsu K, Yano Y, Komatsu S, Tanaka M, Kido M, Fukumoto T. Indication of Liver Transplantation in the Treatment of Newly Categorized Acute-on-Chronic Liver Failure In Japan. Transplant Proc 2021;53:1611-5. [PMID: 33965241 DOI: 10.1016/j.transproceed.2021.03.022] [Reference Citation Analysis]
10 Takaya H, Namisaki T, Sato S, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. J Clin Med. 2020;9. [PMID: 32422875 DOI: 10.3390/jcm9051467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Reference Citation Analysis]